Short answer
Adaptive Biotechnologies Corp (ADPT) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $94M (up 102.4% year over year) with net income of $10M.
Q3 2025 key financials · XBRL
- Revenue
- $94M
- +102.4% YoY · +59.6% QoQ
- Net income
- $10M
- +129.8% YoY · +137.3% QoQ
- Operating margin
- 10.9%
- EPS (diluted)
- $0.07
- +131.8% YoY · +141.2% QoQ
Source: XBRL data from the Adaptive Biotechnologies Corp (ADPT) Q3 2025 10-Q on SEC EDGAR. USD.
Adaptive Biotechnologies Corp Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added risk: Termination of Genentech Agreement in Aug 2025, with wind-down completing Feb 2026 may materially impact business and financial condition
- Most materially updated risk: Loss of exclusive oncology collaboration may reduce Immune Medicine revenue to sequencing service fees only, lowering comparability to prior periods
- Most impactful legal risk: No new similar collaboration agreements, potential collaborator conflicts or actions risking reputation and operational control
- Operational risk: Reduced R&D expenses post-termination may lead to decreased innovation and slower business growth
- Financial risk: Risk of revenue decline in Immune Medicine segment due to narrowing revenue sources after collaboration termination
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Adaptive Biotechnologies Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.